MedTrace Logo

Beta-Cell Function After Near-Normalisation of Blood Glucose

NCT00612950 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2008-02-12

No results posted yet for this study

Summary

The incretin effect is attenuated in patients with type 2 diabetes mellitus partly due to impaired potentiation of beta-cell responsiveness to glucose by glucose dependent insulinotropic polypeptide and glucagon-like peptide-1 respectively. The aim of the present study was to investigate whether 4 weeks of near-normalization of blood glucose could improve the insulin responses to GIP and GLP-1 in patients with type 2 diabetes.

Conditions

Interventions

DRUG

glucagon-like peptide-1,

GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.

DRUG

glucose dependent insulinotropic polypeptide

continuous infusion of GIP (1½ pmol/kg/min) for 120 min.

DRUG

Saline

continuous infusion of Saline for 120 min

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Patricia V Højberg, MD, PHD · University Hospital Hvidovre

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-02-28
Completion
2007-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00612950 on ClinicalTrials.gov